GC
HRTX icon

Grimes & Company’s Heron Therapeutics HRTX Stock Holding History

Grimes & Company’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,863
Closed -$95.2K – 388
2024
Q3 		$95.2K Hold
47,863
– – ﹤0.01% 356
2024
Q2 		$168K Buy
47,863
+893
+2% +$2.74K 0.01% 335
2024
Q1 		$130K Sell
46,970
-893
-2% -$2.25K ﹤0.01% 331
2023
Q4 		$81.4K Sell
47,863
-1,116
-2% -$1.23K ﹤0.01% 320
2023
Q3 		$50.4K Buy
48,979
+1,175
+2% +$1.67K ﹤0.01% 293
2023
Q2 		$55.5K Buy
47,804
+10,106
+27% +$18K ﹤0.01% 300
2023
Q1 		$56.9K Buy
37,698
+21,938
+139% +$54.9K ﹤0.01% 291
2022
Q4 		$39.4K Hold
15,760
– – ﹤0.01% 283
2022
Q3 		$67K Buy
15,760
+224
+1% +$877 ﹤0.01% 266
2022
Q2 		$43K Buy
15,536
+448
+3% +$1.8K ﹤0.01% 269
2022
Q1 		$86K Buy
15,088
+3,561
+31% +$26.1K ﹤0.01% 294
2021
Q4 		$105K Sell
11,527
-1,625
-12% -$16.6K ﹤0.01% 290
2021
Q3 		$141K Buy
13,152
+1,262
+11% +$15.4K 0.01% 292
2021
Q2 		$185K Buy
+11,890
New +$189K 0.01% 289

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Grimes & Company's HRTX Position: Q4 2024 in Review

Grimes & Company sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 47,863 shares — an estimated $95.2K sold.

Grimes & Company first reported a position in HRTX in Q2 2021 and held it in 14 quarters. The position peaked at $185K in Q2 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Grimes & Company reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Grimes & Company sold 47,863 Heron Therapeutics shares in Q4 2024, an estimated $95.2K.
  • Grimes & Company first reported a position in Heron Therapeutics in Q2 2021 and held it in 14 quarters.
  • Grimes & Company's Heron Therapeutics position peaked at $185K in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Grimes & Company's 13F filing for Q4 2024, filed 21 Jan 2025.